A Case of Lupus Podocytopathy

Vineetha Philip, MD, MPH, is a second-year fellow in the adult rheumatology program at Houston Methodist Hospital.

Myriam Guevara, MD, is the program director for the adult rheumatology fellowship program at Houston Methodist Hospital.

Angelina Edwards, MD, is the program director for the nephrology fellowship program at Houston Methodist Hospital.

Ziad M. El-Zataari, MD, is an assistant professor of clinical pathology and laboratory medicine at Houston Methodist Hospital and practices as an academic surgical pathologist with expertise in medical renal pathology.

References

1. Chen D, Hu W. Lupus podocytopathy: A distinct entity of lupus nephritis. J Nephrol. 2018 Oct;31(5):629–634.
2. Hu W, Chen Y, Wang S, et al. Clinical-morphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol. 2016 Apr;11(4):585–592.
3. Oliva-Damaso N, Payan J, Oliva-Damaso E, et al. Lupus podocytopathy: An overview. Adv Chronic Kidney Dis. 2019 Sep;26(5):369–375.
4. Dube GK, Markowitz GS, Radhakrishnan J, et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002 Feb;57(2):120–126.
5. Hertig A, Droz D, Lesavre P, et al. SLE and idiopathic nephrotic syndrome: Coincidence or not? Am J Kidney Dis. 2002 Dec;40(6):1179–1184.
6. Han TS, Schwartz MM, Lewis EJ. Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis. Lupus. 2006;15(2):71–75.
7. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835.
8. Bomback AS, Markowitz GS. Lupus podocytopathy: A distinct entity. Clin J Am Soc Nephrol. 2016 Apr;11(4):547–548.
9. Yu F, Haas M, Glassock R, et al. Redefining lupus nephritis: Clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017 Aug;13(8):483–495.
10. Trivedi S, Zeier M, Reiser J. Role of podocytes in lupus nephritis. Nephrol Dial Transplant. 2009 Dec;24(12):3607–3612.
11. Navarro D, Ferreira AC, Viana H, et al. Morphological indexes: Can they predict lupus nephritis outcomes? A retrospective study. Acta Med Port. 2019 Oct;32(10):635–640.
12. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4):753–779.
13. Bomback AS. Nonproliferative forms of lupus nephritis: An overview. Rheum Dis Clin North Am. 2018 Nov;44(4):561–569.
14. Wang Y, Yu F, Song D, et al. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: A large cohort study from a single centre. Rheumatology (Oxford). 2014;53(7): 1235–1244.
15. Jeruschke S, Alex D, Hoyer PF, Weber S. Protective effects of rituximab on puromycin-induced apoptosis, loss of adhesion and cytoskeletal alterations in human podocytes. Sci Rep. 2022 Jul; 12(1):12297.
16. Wang SF, Chen YH, Chen DQ, et al. Mesangial proliferative lupus nephritis with podocytopathy: A special entity of lupus nephritis. Lupus. 2018 Feb; 27(2):303–311.